GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (MEX:MEDP) » Definitions » Cyclically Adjusted Revenue per Share

Medpace Holdings (MEX:MEDP) Cyclically Adjusted Revenue per Share : MXN776.94 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Medpace Holdings Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medpace Holdings's adjusted revenue per share for the three months ended in Mar. 2025 was MXN366.308. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN776.94 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-25), Medpace Holdings's current stock price is MXN5900.00. Medpace Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN776.94. Medpace Holdings's Cyclically Adjusted PS Ratio of today is 7.59.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Medpace Holdings was 14.47. The lowest was 8.20. And the median was 10.56.


Medpace Holdings Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Medpace Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings Cyclically Adjusted Revenue per Share Chart

Medpace Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 714.30

Medpace Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 488.09 664.02 714.30 776.94

Competitive Comparison of Medpace Holdings's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PS Ratio falls into.


;
;

Medpace Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medpace Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=366.308/134.9266*134.9266
=366.308

Current CPI (Mar. 2025) = 134.9266.

Medpace Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 34.782 100.684 46.611
201509 39.283 100.392 52.797
201512 41.670 99.792 56.341
201603 43.256 100.470 58.091
201606 49.429 101.688 65.586
201609 55.401 101.861 73.385
201612 52.856 101.863 70.013
201703 48.361 102.862 63.436
201706 47.029 103.349 61.398
201709 51.055 104.136 66.151
201712 58.631 104.011 76.058
201803 81.284 105.290 104.164
201806 91.186 106.317 115.724
201809 90.315 106.507 114.414
201812 101.231 105.998 128.859
201903 104.438 107.251 131.388
201906 109.998 108.070 137.334
201909 112.831 108.329 140.533
201912 114.751 108.420 142.805
202003 142.352 108.902 176.371
202006 126.760 108.767 157.247
202009 134.766 109.815 165.583
202012 137.064 109.897 168.281
202103 140.770 111.754 169.959
202106 146.887 114.631 172.893
202109 188.431 115.734 219.679
202112 130.524 117.630 149.717
202203 181.209 121.301 201.564
202206 209.692 125.017 226.314
202209 239.327 125.227 257.865
202212 237.213 125.222 255.597
202303 243.327 127.348 257.808
202306 250.232 128.729 262.280
202309 270.096 129.860 280.635
202312 265.645 129.419 276.949
202403 265.036 131.776 271.372
202406 301.531 132.554 306.929
202409 327.262 133.029 331.930
202412 351.077 133.157 355.742
202503 366.308 134.927 366.308

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Medpace Holdings  (MEX:MEDP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medpace Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5900.00/776.94
=7.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Medpace Holdings was 14.47. The lowest was 8.20. And the median was 10.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medpace Holdings Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.